Finally, the role of mutated NTRK3 as target gene for treatment of non-small cell lung cancer is exploited by clinical trials [67], whereas targeting FGFR2 and EGFR in stomach cancer is considered promising for improving current strategies [68]. This evidence concerns the gene EGFR and gastric neoplasm.